vs
PMV Pharmaceuticals, Inc.（PMVP）与REZOLVE AI PLC（RZLV）财务数据对比。点击上方公司名可切换其他公司
PMV Pharmaceuticals, Inc.的季度营收约是REZOLVE AI PLC的1.0倍（$1.2M vs $1.2M），REZOLVE AI PLC净利率更高（-1078.8% vs -1464.0%，领先385.3%）
PMV Pharmaceuticals是一家临床阶段生物制药企业，专注于开发针对p53抑癌基因突变的精准肿瘤疗法，p53是人类癌症中最常见的突变基因之一。其在研管线主打产品用于治疗难治性实体瘤与血液恶性肿瘤，满足全球肿瘤患者未被满足的医疗需求。
REZOLVE AI PLC是总部位于英国的科技企业，开发人工智能驱动的移动互动与即时交易平台，支持用户直接从音频、视频、印刷内容中完成购买，服务欧洲、北美及部分亚太市场的零售、消费品与媒体客户。
PMVP vs RZLV — 直观对比
营收规模更大
PMVP
是对方的1.0倍
$1.2M
净利率更高
RZLV
高出385.3%
-1464.0%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $1.2M |
| 净利润 | $-18.0M | $-13.0M |
| 毛利率 | — | — |
| 营业利润率 | -1561.8% | -808.4% |
| 净利率 | -1464.0% | -1078.8% |
| 营收同比 | -46.1% | — |
| 净利润同比 | 21.6% | — |
| 每股收益（稀释后） | $-0.33 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PMVPRZLV
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $1.7M | $1.2M | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $2.3M | — | ||
| Q3 24 | $2.6M | — | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $3.0M | — |
净利润PMVPRZLV
| Q4 25 | $-18.0M | — | ||
| Q3 25 | $-21.1M | — | ||
| Q2 25 | $-21.2M | $-13.0M | ||
| Q1 25 | $-17.4M | — | ||
| Q4 24 | $-23.0M | — | ||
| Q3 24 | $-19.2M | — | ||
| Q2 24 | $-1.2M | — | ||
| Q1 24 | $-15.3M | — |
营业利润率PMVPRZLV
| Q4 25 | -1561.8% | — | ||
| Q3 25 | -1521.8% | — | ||
| Q2 25 | -1353.8% | -808.4% | ||
| Q1 25 | -1114.4% | — | ||
| Q4 24 | -1100.5% | — | ||
| Q3 24 | -837.0% | — | ||
| Q2 24 | -720.1% | — | ||
| Q1 24 | -617.2% | — |
净利率PMVPRZLV
| Q4 25 | -1464.0% | — | ||
| Q3 25 | -1422.9% | — | ||
| Q2 25 | -1255.0% | -1078.8% | ||
| Q1 25 | -901.1% | — | ||
| Q4 24 | -1005.7% | — | ||
| Q3 24 | -735.2% | — | ||
| Q2 24 | -43.3% | — | ||
| Q1 24 | -517.3% | — |
每股收益（稀释后）PMVPRZLV
| Q4 25 | $-0.33 | — | ||
| Q3 25 | $-0.40 | — | ||
| Q2 25 | $-0.41 | — | ||
| Q1 25 | $-0.34 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-0.37 | — | ||
| Q2 24 | $-0.02 | — | ||
| Q1 24 | $-0.30 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $112.9M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $104.7M | $-14.3M |
| 总资产 | $116.6M | $80.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PMVPRZLV
| Q4 25 | $112.9M | — | ||
| Q3 25 | $129.3M | — | ||
| Q2 25 | $142.3M | — | ||
| Q1 25 | $160.4M | — | ||
| Q4 24 | $169.5M | — | ||
| Q3 24 | $182.8M | — | ||
| Q2 24 | $212.9M | — | ||
| Q1 24 | $197.9M | — |
股东权益PMVPRZLV
| Q4 25 | $104.7M | — | ||
| Q3 25 | $121.0M | — | ||
| Q2 25 | $140.6M | $-14.3M | ||
| Q1 25 | $160.1M | — | ||
| Q4 24 | $176.1M | — | ||
| Q3 24 | $197.9M | — | ||
| Q2 24 | $214.3M | — | ||
| Q1 24 | $212.7M | — |
总资产PMVPRZLV
| Q4 25 | $116.6M | — | ||
| Q3 25 | $133.8M | — | ||
| Q2 25 | $152.9M | $80.1M | ||
| Q1 25 | $170.6M | — | ||
| Q4 24 | $191.3M | — | ||
| Q3 24 | $223.5M | — | ||
| Q2 24 | $237.5M | — | ||
| Q1 24 | $236.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-17.2M | $-4.9M |
| 自由现金流经营现金流 - 资本支出 | $-17.2M | — |
| 自由现金流率自由现金流/营收 | -1396.4% | — |
| 资本支出强度资本支出/营收 | 1.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-73.6M | — |
8季度趋势，按日历期对齐
经营现金流PMVPRZLV
| Q4 25 | $-17.2M | — | ||
| Q3 25 | $-19.8M | — | ||
| Q2 25 | $-18.3M | $-4.9M | ||
| Q1 25 | $-18.3M | — | ||
| Q4 24 | $-16.7M | — | ||
| Q3 24 | $-16.8M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-16.2M | — |
自由现金流PMVPRZLV
| Q4 25 | $-17.2M | — | ||
| Q3 25 | $-19.8M | — | ||
| Q2 25 | $-18.3M | — | ||
| Q1 25 | $-18.3M | — | ||
| Q4 24 | $-16.7M | — | ||
| Q3 24 | $-16.8M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-16.8M | — |
自由现金流率PMVPRZLV
| Q4 25 | -1396.4% | — | ||
| Q3 25 | -1339.3% | — | ||
| Q2 25 | -1083.6% | — | ||
| Q1 25 | -944.2% | — | ||
| Q4 24 | -731.0% | — | ||
| Q3 24 | -644.0% | — | ||
| Q2 24 | -57.2% | — | ||
| Q1 24 | -568.4% | — |
资本支出强度PMVPRZLV
| Q4 25 | 1.2% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 20.1% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
